Please use this identifier to cite or link to this item:
Title: Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study
Authors: Naranjo, Antonio 
Sokka, Tuulikki
Descalzo, Miguel A.
Calvo-Alén, Jaime
Hørslev-Petersen, Kim
Luukkainen, Reijo K.
Combe, Bernard
Burmester, Gerd R.
Devlin, Joe
Ferraccioli, Gianfranco
Morelli, Alessia
Hoekstra, Monique
Majdan, Maria
Sadkiewicz, Stefan
Belmonte, Miguel
Holmqvist, Ann Carin
Choy, Ernest
Tunc, Recep
Dimic, Aleksander
Bergman, Martin
Toloza, Sergio
Pincus, Theodore
UNESCO Clasification: 32 Ciencias médicas
320501 Cardiología
320509 Reumatología
Keywords: Myocardial-Infarction
Inflammatory Polyarthritis
Endothelial Function
Inception Cohort, et al
Issue Date: 2008
Journal: Arthritis Research and Therapy 
Abstract: Introduction We analyzed the prevalence of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) and its association with traditional CV risk factors, clinical features of RA, and the use of disease- modifying antirheumatic drugs (DMARDs) in a multinational cross-sectional cohort of nonselected consecutive outpatients with RA (The Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis Program, or QUEST-RA) who were receiving regular clinical care.Methods The study involved a clinical assessment by a rheumatologist and a self-report questionnaire by patients. The clinical assessment included a review of clinical features of RA and exposure to DMARDs over the course of RA. Comorbidities were recorded; CV morbidity included myocardial infarction, angina, coronary disease, coronary bypass surgery, and stroke. Traditional risk factors recorded were hypertension, hyperlipidemia, diabetes mellitus, smoking, physical inactivity, and body mass index. Unadjusted and adjusted hazard ratios (HRs) (95% confidence interval [CI]) for CV morbidity were calculated using Cox proportional hazard regression models.Results Between January 2005 and October 2006, the QUEST-RA project included 4,363 patients from 48 sites in 15 countries; 78% were female, more than 90% were Caucasian, and the mean age was 57 years. The prevalence for lifetime CV events in the entire sample was 3.2% for myocardial infarction, 1.9% for stroke, and 9.3% for any CV event. The prevalence for CV risk factors was 32% for hypertension, 14% for hyperlipidemia, 8% for diabetes, 43% for ever-smoking, 73% for physical inactivity, and 18% for obesity. Traditional risk factors except obesity and physical inactivity were significantly associated with CV morbidity. There was an association between any CV event and age and male gender and between extra-articular disease and myocardial infarction. Prolonged exposure to methotrexate (HR 0.85; 95% CI 0.81 to 0.89), leflunomide (HR 0.59; 95% CI 0.43 to 0.79), sulfasalazine (HR 0.92; 95% CI 0.87 to 0.98), glucocorticoids (HR 0.95; 95% CI 0.92 to 0.98), and biologic agents (HR 0.42; 95% CI 0.21 to 0.81; P < 0.05) was associated with a reduction of the risk of CV morbidity; analyses were adjusted for traditional risk factors and countries.Conclusion In conclusion, prolonged use of treatments such as methotrexate, sulfasalazine, leflunomide, glucocorticoids, and tumor necrosis factor-alpha blockers appears to be associated with a reduced risk of CV disease. In addition to traditional risk factors, extra-articular disease was associated with the occurrence of myocardial infarction in patients with RA.
ISSN: 1478-6354
DOI: 10.1186/ar2383
Source: Arthritis Research & Therapy[ISSN 1478-6354],v. 10 (2) (Marzo 2008)
Appears in Collections:Artículos
Show full item record


checked on Aug 7, 2022


checked on Aug 7, 2022

Page view(s)

checked on Jun 25, 2022

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.